Shanghai Henlius Biologics divulges new KAT6A and KAT6B inhibitors

March 13, 2025

Shanghai Henlius Biologics Co. Ltd. has synthesized histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for March 25, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 25, 2025

Lost in trans-lation? Trump’s mouse charge doesn’t click

BioWorld

U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example...

Gene therapy efforts active, despite low Bluebird, 2seventy bids

BioWorld

Bristol Myers Squibb Co.’s decision this week to snag Bluebird Bio Inc. spinout 2seventy Bio Inc. for $102 million net – just weeks after investors bid $30...

US NIH grant peer review to get a bit of a makeover

BioWorld

Looking to shave $65 million from its annual expenditures while streamlining the first stage of its two-level grant review process, the U.S. NIH is proposing to...